Indication and Important Safety Information | Full Prescribing Information
Forms

Download the Somatuline® Depot (lanreotide) Injection Referral Form, print for use, ensure that both the patient and physician sign the form and provide completed form to Tercica fax (1-800-548-7036) or a sales rep.

You must have Adobe Acrobat Reader to view these files. If you do not have Adobe Acrobat Reader installed on your computer, you can download it for free.

ADOBE Get Acrobat Reader

Adobe®, the Adobe logo, Acrobat®, and the Acrobat logo are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

 

How to inject Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline® Depot (lanreotide) Injection.

 
 

Who should take Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation. It is also for patients who cannot tolerate surgery or radiation.1 Find out more about who should take Somatuline® Depot (lanreotide) Injection.

 
 

Read Full Prescribing Information

View the Full Prescribing Information for Somatuline® Depot (lanreotide) Injection.

 

Indication and Important Safety Information

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).

For Full Prescribing Information, click here.